UBS Group AG Purchases 252,766 Shares of LivaNova PLC $LIVN

UBS Group AG increased its position in LivaNova PLC (NASDAQ:LIVN) by 85.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 547,554 shares of the company’s stock after purchasing an additional 252,766 shares during the period. UBS Group AG’s holdings in LivaNova were worth $33,691,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Arizona State Retirement System boosted its stake in LivaNova by 1.7% in the 3rd quarter. Arizona State Retirement System now owns 16,129 shares of the company’s stock worth $845,000 after purchasing an additional 274 shares in the last quarter. Bayforest Capital Ltd boosted its stake in LivaNova by 44.8% in the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after purchasing an additional 284 shares in the last quarter. UMB Bank n.a. boosted its stake in LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after purchasing an additional 306 shares in the last quarter. California State Teachers Retirement System boosted its stake in LivaNova by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after purchasing an additional 458 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in LivaNova by 31.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,901 shares of the company’s stock worth $100,000 after purchasing an additional 460 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

LIVN opened at $71.86 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.16 and a current ratio of 1.33. The stock has a market capitalization of $3.95 billion, a P/E ratio of 36.85 and a beta of 0.82. The company’s 50-day simple moving average is $64.01 and its two-hundred day simple moving average is $62.15. LivaNova PLC has a 52-week low of $41.01 and a 52-week high of $72.51.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts predict that LivaNova PLC will post 3.66 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LIVN. Piper Sandler reiterated an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research note on Wednesday, February 25th. Mizuho upped their price target on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday. Finally, Robert W. Baird lowered their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $77.22.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.